$122 Million is the total value of Knoll Capital Management, LLC's 22 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 41.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CRBP | Corbus Pharmaceuticals HLDGS | $34,552,000 | -0.3% | 4,985,870 | 0.0% | 28.29% | +7.4% | |
| BHVN | Biohaven Pharmactl Hldg Co L | $32,834,000 | -14.9% | 749,815 | 0.0% | 26.88% | -8.3% | |
| ABEO | Abeona Therapeutics Inc | $11,280,000 | -35.1% | 2,359,767 | 0.0% | 9.23% | -30.0% | |
| BX | Blackstone Group LP | $6,796,000 | +27.0% | 153,000 | 0.0% | 5.56% | +36.9% | |
| KRYS | Sell | Krystal Biotech Inc | $5,923,000 | -14.3% | 147,090 | -30.0% | 4.85% | -7.6% |
| MO | Altria Group Inc | $4,262,000 | -17.5% | 90,000 | 0.0% | 3.49% | -11.2% | |
| APLT | New | Applied Therapeutics Inc | $3,849,000 | – | 467,071 | +100.0% | 3.15% | – |
| EIGR | Buy | Eiger Biopharmaceuticals Inc | $3,713,000 | +252.9% | 350,238 | +365.5% | 3.04% | +280.5% |
| ALDX | Buy | Aldeyra Therapeutics Inc | $3,176,000 | -27.3% | 529,390 | +9.4% | 2.60% | -21.7% |
| KBA | Kraneshares TRbosera msci ch | $2,972,000 | -2.9% | 96,000 | 0.0% | 2.43% | +4.6% | |
| AVXL | Anavex Life Sciences Corp | $2,441,000 | +10.5% | 724,205 | 0.0% | 2.00% | +19.0% | |
| DD | New | Dupont de Nemours Inc | $2,252,000 | – | 30,000 | +100.0% | 1.84% | – |
| GLMD | Galmed Pharmaceuticals Ltd | $1,515,000 | -10.0% | 206,099 | 0.0% | 1.24% | -3.1% | |
| DOW | New | Dow Inc | $1,479,000 | – | 30,000 | +100.0% | 1.21% | – |
| ENTX | Entera Bio Ltd | $1,474,000 | -28.3% | 475,540 | 0.0% | 1.21% | -22.8% | |
| MTEM | Molecular Templates | $951,000 | +43.7% | 113,905 | 0.0% | 0.78% | +54.9% | |
| CTVA | New | Corteva Inc | $887,000 | – | 30,000 | +100.0% | 0.73% | – |
| ECOR | Electrocore Inc | $794,000 | -71.4% | 396,825 | 0.0% | 0.65% | -69.2% | |
| SNGX | Soligenix Inc. | $595,000 | -22.4% | 837,800 | 0.0% | 0.49% | -16.5% | |
| CATS | New | Catasys Inc | $281,000 | – | 14,614 | +100.0% | 0.23% | – |
| LPCN | Lipocine Inc New | $97,000 | -16.4% | 50,000 | 0.0% | 0.08% | -10.2% | |
| VBLT | New | Vascular Biogenics Ltd | $28,000 | – | 21,400 | +100.0% | 0.02% | – |
| DWDP | Exit | DowDupont Inc | $0 | – | -90,000 | -100.0% | -3.65% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Aldeyra Therapeutics Inc | 35 | Q3 2023 | 31.6% |
| Corbus Pharmaceuticals HLDGS | 30 | Q3 2022 | 46.5% |
| Abeona Therapeutics Inc | 30 | Q3 2022 | 34.8% |
| Biohaven Pharmactl Hldg Co L | 26 | Q3 2023 | 79.6% |
| Entera Bio Ltd | 22 | Q3 2023 | 7.8% |
| Ampio Pharmaceuticals Inc. | 21 | Q2 2018 | 11.0% |
| Soligenix Inc. | 20 | Q3 2022 | 1.7% |
| Eiger Biopharmaceuticals Inc | 19 | Q3 2022 | 5.8% |
| Applied Therapeutics Inc | 18 | Q3 2023 | 19.7% |
| Alcobra Ltd | 18 | Q3 2017 | 6.5% |
View Knoll Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| HOOKIPA Pharma Inc. | June 20, 2023 | 5,517,385 | 6.8% |
| Applied Therapeutics Inc. | January 23, 2023 | 3,450,000 | 7.2% |
| Orgenesis Inc. | August 14, 2020 | 1,316,364 | 5.9% |
| Corbus Pharmaceuticals Holdings, Inc. | February 14, 2020 | 5,045,870 | 7.1% |
| ABEONA THERAPEUTICS INC. | February 14, 2018 | 2,359,767 | 5.0% |
| SOLIGENIX, INC. | November 13, 2017 | 870,000 | 9.9% |
| ABEONA THERAPEUTICS INC. | February 14, 2017 | 2,359,767 | 5.9% |
| ALCOBRA LTD. | February 14, 2017 | 1,205,498 | 4.4% |
| Ampio Pharmaceuticals, Inc. | February 14, 2017 | 2,738,322 | 4.8% |
| RITTER PHARMACEUTICALS INC | February 14, 2017 | 952,434 | 8.2% |
View Knoll Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-01-16 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-04 |
| 13F-HR | 2023-08-15 |
| SC 13G | 2023-06-20 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-23 |
| 13F-HR | 2022-11-14 |
View Knoll Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.